{"doi":"10.1002/mds.29734","title":"An Exploratory, Randomized, <scp>Double‐Blind</scp> Clinical Trial of Dipraglurant for Blepharospasm","abstract":"BACKGROUND: Blepharospasm is treated with botulinum toxin, but obtaining satisfactory results is sometimes challenging. OBJECTIVE: The aim is to conduct an exploratory trial of oral dipraglurant for blepharospasm. METHODS: This study was an exploratory, phase 2a, randomized, double-blind, placebo-controlled trial of 15 participants who were assigned to receive a placebo or dipraglurant (50 or 100 mg) and assessed over 2 days, 1 and 2 hours following dosing. Outcome measures included multiple scales rated by clinicians or participants, digital video, and a wearable sensor. RESULTS: Dipraglurant was well tolerated, with no obvious impact on any of the measurement outcomes. Power analyses suggested fewer subjects would be required for studies using a within-subject versus independent group design, especially for certain measures. Some outcome measures appeared more suitable than others. CONCLUSION: Although dipraglurant appeared well tolerated, it did not produce a trend for clinical benefit. The results provide valuable information for planning further trials in blepharospasm. © 2024 International Parkinson and Movement Disorder Society.","journal":"Movement Disorders","year":2024,"id":453300,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":8,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9538,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1016712,"name":"Hodam Kim","orcid":"0000-0003-0439-6236","position":1,"is_corresponding":false},{"id":107322,"name":"Dongdong Chen","orcid":"0000-0002-4642-4373","position":2,"is_corresponding":false},{"id":1276217,"name":"Cameron I. Yeo","orcid":null,"position":3,"is_corresponding":false},{"id":713356,"name":"Ashok Reddy Dinasarapu","orcid":"0000-0002-1423-1518","position":4,"is_corresponding":false},{"id":687893,"name":"Laura Scorr","orcid":"0000-0002-4569-6393","position":5,"is_corresponding":false},{"id":242213,"name":"Woon‐Hong Yeo","orcid":"0000-0002-5526-3882","position":6,"is_corresponding":false},{"id":694108,"name":"David Peterson","orcid":"0000-0001-8151-4078","position":7,"is_corresponding":false},{"id":1276218,"name":"Hilde Williams","orcid":null,"position":8,"is_corresponding":false},{"id":1276219,"name":"April Ruby","orcid":null,"position":9,"is_corresponding":false},{"id":1275830,"name":"Roger Mills","orcid":"0000-0002-3993-4180","position":10,"is_corresponding":false},{"id":350763,"name":"Hyder A. Jinnah","orcid":"0000-0003-1531-3969","position":11,"is_corresponding":false},{"id":694106,"name":"Gamze Kilic‐Berkmen","orcid":"0000-0002-9156-5706","position":0,"is_corresponding":true}],"reference_count":42,"raw_metadata":null,"created_at":"2026-07-19T02:02:58.784290Z","pmid":"38310362","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}